Novavax, Inc.
General ticker "NVAX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Novavax, Inc. follows the US Stock Market performance with the rate: 44.2%.
Estimated limits based on current volatility of 4.5%: low 10.07$, high 11.02$
Factors to consider:
- Total employees count: 952 (-38.3%) as of 2024
- North America accounted for 9.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: History of losses, Funding requirements, Labor/talent shortage/retention, Dependence on successful vaccine development, Regulatory and compliance
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.60$, 9.59$]
- 2026-12-31 to 2027-12-31 estimated range: [3.57$, 9.42$]
Financial Metrics affecting the NVAX estimates:
- Positive: with PPE of 2.2 at the end of fiscal year the price was low
- Negative: negative Operating cash flow
- Positive: Operating profit margin, % of 40.30 > 18.39
- Positive: Return on assets ratio (scaled to [-100,100]) of 27.23 > 6.06
- Negative: negative Industry operating income (median)
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
- Negative: Investing cash flow per share per price, % of -7.15 <= -4.41
Short-term NVAX quotes
Long-term NVAX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $983.71MM | $682.16MM | $1,123.48MM |
| Operating Expenses | $1,550.22MM | $931.09MM | $670.68MM |
| Operating Income | $-566.51MM | $-248.93MM | $452.80MM |
| Non-Operating Income | $23.48MM | $72.32MM | $-10.63MM |
| Interest Expense | $14.42MM | $20.07MM | $22.55MM |
| R&D Expense | $737.50MM | $391.17MM | $342.32MM |
| Income(Loss) | $-543.03MM | $-176.62MM | $442.17MM |
| Taxes | $2.03MM | $10.88MM | $1.86MM |
| Net Income(Loss)* | $-545.06MM | $-187.50MM | $440.30MM |
| Stockholders Equity | $-716.93MM | $-623.84MM | $-127.75MM |
| Inventory | $41.70MM | $8.75MM | $11.54MM |
| Assets | $1,797.49MM | $1,560.42MM | $1,176.51MM |
| Operating Cash Flow | $-713.97MM | $-87.26MM | $-244.63MM |
| Capital expenditure | $58.81MM | $13.06MM | $5.56MM |
| Investing Cash Flow | $-58.81MM | $-204.04MM | $-78.27MM |
| Financing Cash Flow | $4.47MM | $260.58MM | $27.74MM |
| Earnings Per Share** | $-5.41 | $-1.23 | $2.72 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.